{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:26:11Z","timestamp":1787678771160,"version":"build-2784847793"},"reference-count":138,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["NANOTEC"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>An autoimmune-mediated dermatological ailment featuring recurrent episodes is\nacknowledged as psoriasis. Around the world, 2\u20133% of people suffer from this autoimmune skin condition.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objectives:<\/jats:title>\n<jats:p>The primary goal of the current review is to analyse and determine the effectiveness of conventional\nand emerging nano technological strategies to alleviate psoriasis and discuss future perspectives.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>A thorough search of numerous electronic databases, including Science Direct, Scopus,\nGoogle Scholar, Clinical Trials, Google Patents, Research Gate, and PubMed, yielded all the data used\nin this review paper about the management of psoriasis via various anti-psoriatic agent and nanotechnology\napproaches. Keywords such as topical, liposomes, niosomes, micro needles, clinical trials, patents,\npathogenesis, biosimilars, cytokines, and other pertinent words were investigated.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Nano technological approaches are gaining prominence since they enable targeted delivery,\nrapid onset of action with limited systemic exposure. Researchers have investigated innovative, alternative\ntherapeutic approaches that are both secure and efficient for treating psoriatic conditions. Further,\nthe potential role of numerous psoriatic conventional therapies has been explored. The patents granted\nor in process to address psoriasis via topical route have been well explored. Modern nanotechnology has\nmade it possible for pharmaceuticals to be delivered with improved physical, chemical, pharmacokinetic,\nand pharmacodynamic qualities. Despite extensive research complete cure for psoriasis is hampered.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Relying on the extensive literature review, it can be inferred that nanoparticles based novel\ndelivery strategies have the possibility of enhancing the pharmacological activity and eliminating or resolving\nproblems associated with this ailment. The different drug delivery systems available for the\ntreatment of psoriasis along with the clinical trials in different stages, patents in process and granted, the\ncommercialized status of therapeutic molecules, and the future of research in this area have been thoroughly\nreviewed.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1872210517666230601124620","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T10:38:01Z","timestamp":1685702281000},"page":"259-277","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Recent Advancements in Novel Formulations of Anti-psoriatic Agents for\nEffective Delivery: Clinical Importance and Patent Survey"],"prefix":"10.2174","volume":"18","author":[{"given":"Nikhil","family":"Dadwal","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, ISF College of Pharmacy, Moga, 142 001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balak Das","family":"Kurmi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, ISF College of Pharmacy, Moga, 142 001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilpreet","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, ISF College of Pharmacy, Moga, 142 001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrinder","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, ISF College of Pharmacy, Moga, 142 001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","volume":"370","author":"Griffiths C.E.M.","year":"2007","unstructured":"Griffiths C.E.M.; Barker J.N.W.N.; Pathogenesis and clinical features of psoriasis. Lancet  2007,370(9583),263-271","journal-title":"Lancet"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/bjd.12371","volume":"169","author":"Remr\u00f6d C.","year":"2013","unstructured":"Remr\u00f6d C.; Sj\u00f6str\u00f6m K.; Svensson \u00c5.; Psychological differences between early- and late-onset psoriasis: A study of personality traits, anxiety and depression in psoriasis. Br J Dermatol  2013,169(2),344-350","journal-title":"Br J Dermatol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","volume":"386","author":"Boehncke W.H.","year":"2015","unstructured":"Boehncke W.H.; Sch\u00f6n M.P.; Psoriasis. Lancet  2015,386(9997),983-994","journal-title":"Lancet"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/09546630701364768","volume":"19","author":"Gottlieb A.B.","year":"2008","unstructured":"Gottlieb A.B.; Chao C.; Dann F.; Psoriasis comorbidities. J Dermatolog Treat  2008,19(1),5-21","journal-title":"J Dermatolog Treat"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"A107","DOI":"10.1016\/j.jval.2012.03.580","volume":"15","author":"Fujii R.K.","year":"2012","unstructured":"Fujii R.K.; Mould J.F.; Tang B.; PSY46 Burden of disease in patients with diagnosed psoriasis in Brazil: Results from 2011 National Health and Wellness Survey (NHWS). Value Health  2012,15(4),A107","journal-title":"Value Health"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/psb.1059","volume":"24","author":"Dvorakova V.","year":"2013","unstructured":"Dvorakova V.; Markham T.; Psoriasis: Current treatment options and recent advances. Prescriber  2013,24(10),13-20","journal-title":"Prescriber"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"Griffiths C.E.M.","year":"2021","unstructured":"Griffiths C.E.M.; Armstrong A.W.; Gudjonsson J.E.; Barker J.N.W.N.; Psoriasis. Lancet  2021,397(10281),1301-1315","journal-title":"Lancet"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jconrel.2016.07.003","volume":"239","author":"Sala M.","year":"2016","unstructured":"Sala M.; Elaissari A.; Fessi H.; Advances in psoriasis physiopathology and treatments: Up to date of mechanistic insights and perspectives of novel therapies based on innovative skin drug delivery systems (ISDDS). J Control Release  2016,239,182-202","journal-title":"J Control Release"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.ijpharm.2014.06.001","volume":"471","author":"Zhang Y.T.","year":"2014","unstructured":"Zhang Y.T.; Shen L.N.; Wu Z.H.; Zhao J.H.; Feng N.P.; Comparison of ethosomes and liposomes for skin delivery of psoralen for psoriasis therapy. Int J Pharm  2014,471(1-2),449-452","journal-title":"Int J Pharm"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1208\/s12249-021-01966-3","volume":"22","author":"Rodr\u00edguez-Luna A.","year":"2021","unstructured":"Rodr\u00edguez-Luna A.; Talero E.; \u00c1vila-Rom\u00e1n J.; Preparation and in vivo evaluation of rosmarinic acid-loaded transethosomes after percutaneous application on a psoriasis animal model. AAPS PharmSciTech  2021,22(3),103","journal-title":"AAPS PharmSciTech"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s13555-021-00560-6","volume":"11","author":"Lebwohl M.G.","year":"2021","unstructured":"Lebwohl M.G.; Tanghetti E.A.; Stein Gold L.; Del Rosso J.Q.; Gilyadov N.K.; Jacobson A.; Fixed-combination halobetasol propionate and tazarotene in the treatment of psoriasis: Narrative review of mechanisms of action and therapeutic benefits. Dermatol Ther  2021,11(4),1157-1174","journal-title":"Dermatol Ther"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s13555-021-00611-y","volume":"11","author":"Piquero-Casals J.","year":"2021","unstructured":"Piquero-Casals J.; Morgado-Carrasco D.; Granger C.; Trull\u00e0s C.; Jes\u00fas-Silva A.; Krutmann J.; Urea in dermatology: A review of its emollient, moisturizing, keratolytic, skin barrier enhancing and antimicrobial properties. Dermatol Ther  2021,11(6),1905-1915","journal-title":"Dermatol Ther"},{"key":"ref=13","author":"Birkir S.","year":"2016","unstructured":"Birkir S.; Use of cgrp antagonist compounds for treatment of psoriasis.  2016"},{"key":"ref=14","author":"Campbell T","year":"2022","unstructured":"Campbell T; Zhao Z; Yeung SC; Imidazopyridine derivatives as alpha4beta7 integrin inhibitors.  2022"},{"key":"ref=15","author":"Cunbo MA","year":"2022","unstructured":"Cunbo MA; Panliang GAO; Shaojing HU; Novel heterocyclic derivatives useful as SHP2 inhibitors.  2022"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/1346-8138.15913","volume":"48","author":"Yamanaka K.","year":"2021","unstructured":"Yamanaka K.; Yamamoto O.; Honda T.; Pathophysiology of psoriasis: A review. J Dermatol  2021,48(6),722-731","journal-title":"J Dermatol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","volume":"140","author":"Hawkes J.E.","year":"2017","unstructured":"Hawkes J.E.; Chan T.C.; Krueger J.G.; Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol  2017,140(3),645-653","journal-title":"J Allergy Clin Immunol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3389\/fimmu.2018.01323","volume":"9","author":"Sch\u00f6n M.P.","year":"2018","unstructured":"Sch\u00f6n M.P.; Erpenbeck L.; The interleukin-23\/interleukin-17 axis links adaptive and innate immunity in psoriasis. Front Immunol  2018,9,1323","journal-title":"Front Immunol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/j.1365-2133.2008.08769.x","volume":"159","author":"Nograles K.E.","year":"2008","unstructured":"Nograles K.E.; Zaba L.C.; Guttman-Yassky E.; Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol  2008,159(5),1092-1102","journal-title":"Br J Dermatol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s11926-007-0075-1","volume":"9","author":"Fitch E.","year":"2007","unstructured":"Fitch E.; Harper E.; Skorcheva I.; Kurtz S.E.; Blauvelt A.; Pathophysiology of psoriasis: Recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep  2007,9(6),461-467","journal-title":"Curr Rheumatol Rep"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.immuni.2011.02.012","volume":"34","author":"Iwakura Y.","year":"2011","unstructured":"Iwakura Y.; Ishigame H.; Saijo S.; Nakae S.; Functional specialization of interleukin-17 family members. Immunity  2011,34(2),149-162","journal-title":"Immunity"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41584-018-0155-9","volume":"15","author":"O\u2019Shea J.J.","year":"2019","unstructured":"O\u2019Shea J.J.; Gadina M.; Selective Janus kinase inhibitors come of age. Nat Rev Rheumatol  2019,15(2),74-75","journal-title":"Nat Rev Rheumatol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.coi.2007.04.005","volume":"19","author":"Stockinger B.","year":"2007","unstructured":"Stockinger B.; Veldhoen M.; Differentiation and function of Th17 T cells. Curr Opin Immunol  2007,19(3),281-286","journal-title":"Curr Opin Immunol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"5904","DOI":"10.4049\/jimmunol.0900732","volume":"182","author":"Awasthi A.","year":"2009","unstructured":"Awasthi A.; Riol-Blanco L.; J\u00e4ger A.; Cutting edge: IL-23 receptor gfp reporter mice reveal distinct populations of IL-17-producing cells. J Immunol  2009,182(10),5904-5908","journal-title":"J Immunol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/jid.2012.194","volume":"133","author":"Martin D.A.","year":"2013","unstructured":"Martin D.A.; Towne J.E.; Kricorian G.; The emerging role of IL-17 in the pathogenesis of psoriasis: Preclinical and clinical findings. J Invest Dermatol  2013,133(1),17-26","journal-title":"J Invest Dermatol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1038\/jid.2014.308","volume":"134","author":"Witte E.","year":"2014","unstructured":"Witte E.; Kokolakis G.; Witte K.; IL-19 is a component of the pathogenetic IL-23\/IL-17 cascade in psoriasis. J Invest Dermatol  2014,134(11),2757-2767","journal-title":"J Invest Dermatol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.biopha.2018.06.136","volume":"106","author":"Rapalli V.K.","year":"2018","unstructured":"Rapalli V.K.; Singhvi G.; Dubey S.K.; Gupta G.; Chellappan D.K.; Dua K.; Emerging landscape in psoriasis management: From topical application to targeting biomolecules. Biomed Pharmacother  2018,106,707-713","journal-title":"Biomed Pharmacother"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s13555-018-0230-9","volume":"8","author":"Carrascosa J.M.","year":"2018","unstructured":"Carrascosa J.M.; Jacobs I.; Petersel D.; Strohal R.; Biosimilar drugs for psoriasis: Principles, present, and near future. Dermatol Ther  2018,8(2),173-194","journal-title":"Dermatol Ther"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/joim.12432","volume":"279","author":"Isaacs J.D.","year":"2016","unstructured":"Isaacs J.D.; Cutolo M.; Keystone E.C.; Park W.; Braun J.; Biosimilars in immune\u2010mediated inflammatory diseases: initial lessons from the first approved biosimilar anti\u2010tumour necrosis factor monoclonal antibody. J Intern Med  2016,279(1),41-59","journal-title":"J Intern Med"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.amjms.2017.12.014","volume":"355","author":"Feldman S.R.","year":"2018","unstructured":"Feldman S.R.; Bagel J.; Namak S.; Biosimilars for immune-mediated chronic diseases in primary care: What a practicing physician needs to know. Am J Med Sci  2018,355(5),411-417","journal-title":"Am J Med Sci"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"Gossec L.","year":"2016","unstructured":"Gossec L.; Smolen J.S.; Ramiro S.; European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis  2016,75(3),499-510","journal-title":"Ann Rheum Dis"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/jdv.14114","volume":"31","author":"Gisondi P.","year":"2017","unstructured":"Gisondi P.; Altomare G.; Ayala F.; Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol  2017,31(5),774-790","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.disamonth.2018.06.001","volume":"65","author":"Schadler E.D.","year":"2019","unstructured":"Schadler E.D.; Ortel B.; Mehlis S.L.; Biologics for the primary care physician: Review and treatment of psoriasis. Dis Mon  2019,65(3),51-90","journal-title":"Dis Mon"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/14737167.2020.1800456","volume":"20","author":"Zagni E.","year":"2020","unstructured":"Zagni E.; Colombo D.; Fiocchi M.; Pharmaco-utilization of biologic drugs in patients affected by psoriasis, psoriatic arthritis and ankylosing spondylitis in an Italian real-world setting. Expert Rev Pharmacoecon Outcomes Res  2020,20(5),491-497","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref=35","unstructured":"National psoriasis foudation. Use of ilumya Available from:  https:\/\/www.psoriasis.org\/ilumya\/ (Accessed on: 30th sep, 2022)."},{"key":"ref=36","unstructured":"National psoriasis foudation. Use of Skyrizi Available from:  https:\/\/www.psoriasis.org\/skyrizi\/ (Accessed on: 30th sep, 2022)."},{"key":"ref=37","unstructured":"National psoriasis foudation. Use of tremfya Available from:  https:\/\/www.psoriasis.org\/tremfya\/ (Accessed on: 30th sep, 2022)."},{"key":"ref=38","unstructured":"National psoriasis foudation. Use of Orencia Available from:  https:\/\/www.psoriasis.org\/orencia\/ (Accessed on: 30th sep, 2022)."},{"key":"ref=39","unstructured":"National psoriasis foudation. Use of cosentyx Available from:  https:\/\/www.psoriasis.org\/cose ntyx\/ (Accessed on: 30th sep, 2022)."},{"key":"ref=40","unstructured":"National psoriasis foudation. Use of Taltz Available from:  https:\/\/www.psoriasis.org\/taltz\/ (Accessed on: 30th sep, 2022)."},{"key":"ref=41","unstructured":"National psoriasis foudation. Use of Siliq Available from:  https:\/\/www.psoriasis.org\/siliq\/ (Accessed on: 30th sep, 2022)."},{"key":"ref=42","unstructured":"National psoriasis foudation. Use of Stelara Available from: https:\/\/www.psoriasis.org\/stelara\/ (Accessed on: 30th sep, 2022)."},{"key":"ref=43","unstructured":"National psoriasis foudation. Use of Cimzia Available from:  https:\/\/www.psoriasis.org\/cimzia\/ (Accessed on: 30th sep, 2022)."},{"key":"ref=44","unstructured":"National psoriasis foudation. Use of Enbrel Available from:  https:\/\/www.psoriasis.org\/enbrel\/ (Accessed on: 30th sep, 2022)."},{"key":"ref=45","unstructured":"National psoriasis foudation. Use of Humira Available from:  https:\/\/www.psoriasis.org\/humira\/ (Accessed on: 30th sep, 2022)."},{"key":"ref=46","unstructured":"National psoriasis foudation. Use of Remicade Available from:  https:\/\/www.psoriasis.org\/remicade\/ (Accessed on: 30th sep, 2022)."},{"key":"ref=47","unstructured":"National psoriasis foudation. Use of Simponi Available from:  https:\/\/www.psoriasis.org\/simponi\/ (Accessed on: 30th sep, 2022)."},{"key":"ref=48","unstructured":"National psoriasis foudation. Use of Simponiaria Available from:  https:\/\/www.psoriasis.org\/simponiaria\/ (Accessed on: 30th sep, 2022)."},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"561018","DOI":"10.1155\/2012\/561018","volume":"2012","author":"Uva L.","year":"2012","unstructured":"Uva L.; Miguel D.; Pinheiro C.; Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol  2012,2012,561018","journal-title":"Int J Endocrinol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"e12728","DOI":"10.1111\/dth.12728","volume":"31","author":"Dattola A.","year":"2018","unstructured":"Dattola A.; Silvestri M.; Bennardo L.; Update of calcineurin inhibitors to treat inverse psoriasis: A systematic review. Dermatol Ther  2018,31(6),e12728","journal-title":"Dermatol Ther"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/der2.84","volume":"2","author":"Buechler C.R.","year":"2021","unstructured":"Buechler C.R.; Veenstra J.; Stein Gold L.; New topical therapies for psoriasis. Dermatol Rev  2021,2(5),262-268","journal-title":"Dermatol Rev"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s13671-020-00327-w","volume":"10","author":"Brownstone N.D.","year":"2021","unstructured":"Brownstone N.D.; Bhutani T.; Koo J.; Halobetasol propionate and tazarotene combination lotion 0.01%\/0.045% for psoriasis. Curr Dermatol Rep  2021,10(1),21-25","journal-title":"Curr Dermatol Rep"},{"key":"ref=53","unstructured":"U.S. food and Drug Administration, Drugs@FDA : FDA-Approved Drugs. Available from:  https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.processandApplNo=077227 (Accessed on: 20th aug, 2022)."},{"key":"ref=54","first-page":"12","volume":"4","author":"Dutta S.","year":"2018","unstructured":"Dutta S.; Chawla S.; Kumar S.; Psoriasis: A review of existing therapies and recent advances in treatment. Differentiation  2018,4(1),12-23","journal-title":"Differentiation"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s13555-021-00521-z","volume":"11","author":"Mosca M.","year":"2021","unstructured":"Mosca M.; Hong J.; Hadeler E.; Brownstone N.; Bhutani T.; Liao W.; Scalp psoriasis: A literature review of effective therapies and updated recommendations for practical management. Dermatol Ther  2021,11(3),769-797","journal-title":"Dermatol Ther"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s10856-021-06558-y","volume":"32","author":"Shetty K.","year":"2021","unstructured":"Shetty K.; Sherje A.P.; Nano intervention in topical delivery of corticosteroid for psoriasis and atopic dermatitis\u2014a systematic review. J Mater Sci Mater Med  2021,32(8),88","journal-title":"J Mater Sci Mater Med"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40257-018-0350-0","volume":"19","author":"McClanahan D.R.","year":"2018","unstructured":"McClanahan D.R.; English J.C.; Therapeutics for adult nail psoriasis and nail lichen planus: A guide for clinicians. Am J Clin Dermatol  2018,19(4),559-584","journal-title":"Am J Clin Dermatol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/pde.13422","volume":"35","author":"Kravvas G.","year":"2018","unstructured":"Kravvas G.; Gholam K.; Use of topical therapies for pediatric psoriasis: A systematic review. Pediatr Dermatol  2018,35(3),296-302","journal-title":"Pediatr Dermatol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41416-020-0926-3","volume":"123","author":"Shi H.","year":"2020","unstructured":"Shi H.; Sadler P.J.; How promising is phototherapy for cancer? Br J Cancer  2020,123(6),871-873","journal-title":"Br J Cancer"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1124\/mol.108.051698","volume":"75","author":"Derheimer F.A.","year":"2009","unstructured":"Derheimer F.A.; Hicks J.K.; Paulsen M.T.; Canman C.E.; Ljungman M.; Psoralen-induced DNA interstrand cross-links block transcription and induce p53 in an ataxia-telangiectasia and rad3-related-dependent manner. Mol Pharmacol  2009,75(3),599-607","journal-title":"Mol Pharmacol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1080\/1744666X.2020.1672537","volume":"15","author":"Kem\u00e9ny L.","year":"2019","unstructured":"Kem\u00e9ny L.; Varga E.; Novak Z.; Advances in phototherapy for psoriasis and atopic dermatitis. Expert Rev Clin Immunol  2019,15(11),1205-1214","journal-title":"Expert Rev Clin Immunol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.jaad.2019.04.042","volume":"81","author":"Elmets C.A.","year":"2019","unstructured":"Elmets C.A.; Lim H.W.; Stoff B.; Joint American academy of dermatology\u2013national psoriasis foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol  2019,81(3),775-804","journal-title":"J Am Acad Dermatol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejps.2018.08.031","volume":"124","author":"Alalaiwe A.","year":"2018","unstructured":"Alalaiwe A.; Hung C.F.; Leu Y.L.; The active compounds derived from Psoralea corylifolia for photochemotherapy against psoriasis-like lesions: The relationship between structure and percutaneous absorption. Eur J Pharm Sci  2018,124,114-126","journal-title":"Eur J Pharm Sci"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10103-017-2360-1","volume":"33","author":"Zhang P.","year":"2018","unstructured":"Zhang P.; Wu M.X.; A clinical review of phototherapy for psoriasis. Lasers Med Sci  2018,33(1),173-180","journal-title":"Lasers Med Sci"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.bbacli.2016.09.002","volume":"6","author":"Hamblin M.R.","year":"2016","unstructured":"Hamblin M.R.; Shining light on the head: Photobiomodulation for brain disorders. BBA Clin  2016,6,113-124","journal-title":"BBA Clin"},{"key":"ref=66","unstructured":"Food US. Active ingredients for the control of psoriasis."},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1080\/09546634.2017.1309349","volume":"28","author":"Khalil S.","year":"2017","unstructured":"Khalil S.; Bardawil T.; Stephan C.; Retinoids: A journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects. J Dermatolog Treat  2017,28(8),684-696","journal-title":"J Dermatolog Treat"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1080\/17425255.2018.1515198","volume":"14","author":"Heath M.S.","year":"2018","unstructured":"Heath M.S.; Sahni D.R.; Curry Z.A.; Feldman S.R.; Pharmacokinetics of tazarotene and acitretin in psoriasis. Expert Opin Drug Metab Toxicol  2018,14(9),919-927","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.nano.2009.08.002","volume":"6","author":"Zhao Y.","year":"2010","unstructured":"Zhao Y.; Brown M.B.; Jones S.A.; Pharmaceutical foams: Are they the answer to the dilemma of topical nanoparticles? Nanomedicine  2010,6(2),227-236","journal-title":"Nanomedicine"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1166\/jcsb.2013.1041","volume":"2","author":"Lira A.A.M.","year":"2013","unstructured":"Lira A.A.M.; Cordo P.L.A.; Nogueira E.C.F.; Optimization of topical all-trans retinoic acid penetration using poly-DL-lactide and poly-DL-lactide-co-glycolide microparticles. J Colloid Sci Biotechnol  2013,2(2),123-129","journal-title":"J Colloid Sci Biotechnol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1166\/jcsb.2014.1071","volume":"3","author":"Jada A.","year":"2014","unstructured":"Jada A.; A special issue on inorganic colloidal particles, synthesis, surface properties and applications. J Colloid Sci Biotechnol  2014,3(1),1-2","journal-title":"J Colloid Sci Biotechnol"},{"key":"ref=72","first-page":"336","volume":"8","author":"Lei W.","year":"2013","unstructured":"Lei W.; Yu C.; Lin H.; Zhou X.; Development of tacrolimus-loaded transfersomes for deeper skin penetration enhancement and therapeutic effect improvement in vivo. Asian J Pharm  2013,8(6),336-345","journal-title":"Asian J Pharm"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.phrs.2017.04.014","volume":"121","author":"An J.","year":"2017","unstructured":"An J.; Zhang D.; Wu J.; The acitretin and methotrexate combination therapy for psoriasis vulgaris achieves higher effectiveness and less liver fibrosis. Pharmacol Res  2017,121,158-168","journal-title":"Pharmacol Res"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1080\/10611860802228350","volume":"16","author":"Gregoriadis G.","year":"2008","unstructured":"Gregoriadis G.; Liposome research in drug delivery: The early days. J Drug Target  2008,16(7-8),520-524","journal-title":"J Drug Target"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1080\/08982104.2019.1593449","volume":"30","author":"Walunj M.","year":"2020","unstructured":"Walunj M.; Doppalapudi S.; Bulbake U.; Khan W.; Preparation, characterization, and in vivo evaluation of cyclosporine cationic liposomes for the treatment of psoriasis. J Liposome Res  2020,30(1),68-79","journal-title":"J Liposome Res"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.cis.2013.11.018","volume":"205","author":"Marianecci C.","year":"2014","unstructured":"Marianecci C.; Di Marzio L.; Rinaldi F.; Niosomes from 80s to present: The state of the art. Adv Colloid Interface Sci  2014,205,187-206","journal-title":"Adv Colloid Interface Sci"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"102364","DOI":"10.1016\/j.jddst.2021.102364","volume":"62","author":"Jyothi S.L.","year":"2021","unstructured":"Jyothi S.L.; Krishna K.L.; Ameena S.V.K.; Sankar R.; Pramod K.; Gangadharappa H.V.; Drug delivery systems for the treatment of psoriasis: Current status and prospects. J Drug Deliv Sci Technol  2021,62,102364","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"101581","DOI":"10.1016\/j.jddst.2020.101581","volume":"56","author":"Bhardwaj P.","year":"2020","unstructured":"Bhardwaj P.; Tripathi P.; Gupta R.; Pandey S.; Niosomes: A review on niosomal research in the last decade. J Drug Deliv Sci Technol  2020,56,101581","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejpb.2019.08.015","volume":"144","author":"Chen S.","year":"2019","unstructured":"Chen S.; Hanning S.; Falconer J.; Locke M.; Wen J.; Recent advances in non-ionic surfactant vesicles (niosomes): Fabrication, characterization, pharmaceutical and cosmetic applications. Eur J Pharm Biopharm  2019,144,18-39","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ijpharm.2015.03.020","volume":"485","author":"Abdelbary A.A.","year":"2015","unstructured":"Abdelbary A.A.; AbouGhaly M.H.H.; Design and optimization of topical methotrexate loaded niosomes for enhanced management of psoriasis: Application of Box\u2013Behnken design, in-vitro evaluation and in-vivo skin deposition study. Int J Pharm  2015,485(1-2),235-243","journal-title":"Int J Pharm"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.addr.2012.09.021","volume":"64","author":"Mehnert W.","year":"2012","unstructured":"Mehnert W.; M\u00e4der K.; Solid lipid nanoparticles. Adv Drug Deliv Rev  2012,64,83-101","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1080\/03639045.2019.1576722","volume":"45","author":"Sathe P.","year":"2019","unstructured":"Sathe P.; Saka R.; Kommineni N.; Raza K.; Khan W.; Dithranol-loaded nanostructured lipid carrier-based gel ameliorate psoriasis in imiquimod-induced mice psoriatic plaque model. Drug Dev Ind Pharm  2019,45(5),826-838","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.steroids.2015.05.012","volume":"101","author":"Pradhan M.","year":"2015","unstructured":"Pradhan M.; Singh D.; Murthy S.N.; Singh M.R.; Design, characterization and skin permeating potential of Fluocinolone acetonide loaded nanostructured lipid carriers for topical treatment of psoriasis. Steroids  2015,101,56-63","journal-title":"Steroids"},{"key":"ref=84","first-page":"204","volume":"2","author":"Walve J.","year":"2011","unstructured":"Walve J.; Bakliwal S.; Rane B.; Pawar S.; Transfersomes: A surrogated carrier for transdermal drug delivery system. Int J Appl Biol Pharm Technol  2011,2,204-213","journal-title":"Int J Appl Biol Pharm Technol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1517\/17425247.3.6.727","volume":"3","author":"Benson H.A.E.","year":"2006","unstructured":"Benson H.A.E.; Transfersomes for transdermal drug delivery. Expert Opin Drug Deliv  2006,3(6),727-737","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpb.2016.09.005","volume":"109","author":"Zhang C.Z.","year":"2016","unstructured":"Zhang C.Z.; Niu J.; Chong Y.S.; Porous microspheres as promising vehicles for the topical delivery of poorly soluble asiaticoside accelerate wound healing and inhibit scar formation in vitro and in vivo. Eur J Pharm Biopharm  2016,109,1-13","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=87","first-page":"423","volume":"4","author":"Chaware P.","year":"2015","unstructured":"Chaware P.; Sharma S.; Bhandari A.; Garud A.; Garud N.; Bioadhesive microspheres: A review on preparation and in-vitro characterization. World J Pharm Res  2015,4(2),423-436","journal-title":"World J Pharm Res"},{"key":"ref=88","first-page":"00067","volume":"3","author":"Farah F.H.","year":"2016","unstructured":"Farah F.H.; Magnetic microspheres: A novel drug delivery system. J Anal Pharm Res  2016,3(5),00067","journal-title":"J Anal Pharm Res"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1590\/S1984-82502012000100003","volume":"48","author":"Mukund J.Y.","year":"2012","unstructured":"Mukund J.Y.; Kantilal B.R.; Sudhakar R.N.; Floating microspheres: A review. Braz J Pharm Sci  2012,48(1),17-30","journal-title":"Braz J Pharm Sci"},{"key":"ref=90","first-page":"763","volume":"3","author":"Krishna K.","year":"2013","unstructured":"Krishna K.; Reddy C.; Srikanth S.; A review on microsphere for novel drug delivery system. Int J Res Pharm Chem  2013,3(4),763-767","journal-title":"Int J Res Pharm Chem"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/978-1-4939-6857-2_21","author":"Renkecz T.","year":"2017","unstructured":"Renkecz T.; Horvath V.; Preparation of molecularly imprinted microspheres by precipitation polymerization. Synthetic Antibodies  2017,341-352","journal-title":"Synthetic Antibodies"},{"key":"ref=92","first-page":"1760","volume":"9","author":"Saini S.","year":"2018","unstructured":"Saini S.; Kumar S.; Choudhary M.; Nitesh, Budhwar V. Microspheres as controlled drug delivery system: an updated review. Int J Pharm Sci Res  2018,9(5),1760-1768","journal-title":"Int J Pharm Sci Res"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12951-022-01368-y","volume":"20","author":"Xu J.","year":"2022","unstructured":"Xu J.; Chen H.; Chu Z.; A multifunctional composite hydrogel as an intrinsic and extrinsic coregulator for enhanced therapeutic efficacy for psoriasis. J Nanobiotechnology  2022,20(1),155","journal-title":"J Nanobiotechnology"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ijpharm.2004.12.022","volume":"293","author":"Gupta P.N.","year":"2005","unstructured":"Gupta P.N.; Mishra V.; Rawat A.; Non-invasive vaccine delivery in transfersomes, niosomes and liposomes: A comparative study. Int J Pharm  2005,293(1-2),73-82","journal-title":"Int J Pharm"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s12906-019-2675-5","volume":"19","author":"Negi P.","year":"2019","unstructured":"Negi P.; Sharma I.; Hemrajani C.; Thymoquinone-loaded lipid vesicles: A promising nanomedicine for psoriasis. BMC Complement Altern Med  2019,19(1),334","journal-title":"BMC Complement Altern Med"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S1461-5347(99)00203-5","volume":"2","author":"Liu M.","year":"1999","unstructured":"Liu M.; Fr\u00e9chet J.M.J.; Designing dendrimers for drug delivery. Pharm Sci Technol Today  1999,2(10),393-401","journal-title":"Pharm Sci Technol Today"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"7638","DOI":"10.1021\/ja00177a027","volume":"112","author":"Hawker C.J.","year":"1990","unstructured":"Hawker C.J.; Frechet J.M.J.; Preparation of polymers with controlled molecular architecture. A new convergent approach to dendritic macromolecules. J Am Chem Soc  1990,112(21),7638-7647","journal-title":"J Am Chem Soc"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1039\/b309043b","volume":"33","author":"Boas U.","year":"2004","unstructured":"Boas U.; Heegaard P.M.H.; Dendrimers in drug research. Chem Soc Rev  2004,33(1),43-63","journal-title":"Chem Soc Rev"},{"key":"ref=99","first-page":"142","volume":"3","author":"Tripathy S.","year":"2013","unstructured":"Tripathy S.; Das M.K.; Dendrimers and their applications as novel drug delivery carriers. J Appl Pharm Sci  2013,3(9),142-149","journal-title":"J Appl Pharm Sci"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"e01343","DOI":"10.1016\/j.heliyon.2019.e01343","volume":"5","author":"Tripathi P.K.","year":"2019","unstructured":"Tripathi P.K.; Gorain B.; Choudhury H.; Srivastava A.; Kesharwani P.; Dendrimer entrapped microsponge gel of dithranol for effective topical treatment. Heliyon  2019,5(3),e01343","journal-title":"Heliyon"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"121172","DOI":"10.1016\/j.jhazmat.2019.121172","volume":"383","author":"Wen Z.","year":"2020","unstructured":"Wen Z.; Lu J.; Zhang Y.; Facile inverse micelle fabrication of magnetic ordered mesoporous iron cerium bimetal oxides with excellent performance for arsenic removal from water. J Hazard Mater  2020,383,121172","journal-title":"J Hazard Mater"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jconrel.2021.02.031","volume":"332","author":"Ghezzi M.","year":"2021","unstructured":"Ghezzi M.; Pescina S.; Padula C.; Polymeric micelles in drug delivery: An insight of the techniques for their characterization and assessment in biorelevant conditions. J Control Release  2021,332,312-336","journal-title":"J Control Release"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.xphs.2019.11.010","volume":"109","author":"Supasena W.","year":"2020","unstructured":"Supasena W.; Muangnoi C.; Thaweesest W.; Enhanced antipsoriatic activity of mycophenolic acid against the tnf-\u03b1-induced hacat cell proliferation by conjugated poloxamer micelles. J Pharm Sci  2020,109(2),1153-1160","journal-title":"J Pharm Sci"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0169-409X(00)00103-4","volume":"45","author":"Lawrence M.J.","year":"2000","unstructured":"Lawrence M.J.; Rees G.D.; Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev  2000,45(1),89-121","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1080\/03639045.2017.1395458","volume":"44","author":"Langasco R","year":"2018","unstructured":"Langasco R; Tanr\u0131verdi ST; \u00d6zer \u00d6; Prolonged skin retention of clobetasol propionate by bio-based microemulsions: A potential tool for scalp psoriasis treatment. Drug Dev Ind Pharm  2018,44(3),398-406","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.nano.2017.02.009","volume":"13","author":"Kaur A.","year":"2017","unstructured":"Kaur A.; Katiyar S.S.; Kushwah V.; Jain S.; Nanoemulsion loaded gel for topical co-delivery of clobitasol propionate and calcipotriol in psoriasis. Nanomedicine  2017,13(4),1473-1482","journal-title":"Nanomedicine"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1208\/s12249-019-1306-2","volume":"20","author":"Fahmy A.M.","year":"2019","unstructured":"Fahmy A.M.; El-Setouhy D.A.; Habib B.A.; Tayel S.A.; Enhancement of transdermal delivery of haloperidol via spanlastic dispersions: Entrapment efficiency vs. particle size. AAPS PharmSciTech  2019,20(3),95","journal-title":"AAPS PharmSciTech"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"118556","DOI":"10.1016\/j.ijpharm.2019.118556","volume":"568","author":"Elmowafy E.","year":"2019","unstructured":"Elmowafy E.; El-Gogary R.I.; Ragai M.H.; Nasr M.; Novel antipsoriatic fluidized spanlastic nanovesicles: in vitro physicochemical characterization, ex vivo cutaneous retention and exploratory clinical therapeutic efficacy. Int J Pharm  2019,568,118556","journal-title":"Int J Pharm"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s004030100212","volume":"293","author":"Weerheim A.","year":"2001","unstructured":"Weerheim A.; Ponec M.; Determination of stratum corneum lipid profile by tape stripping in combination with high-performance thin-layer chromatography. Arch Dermatol Res  2001,293(4),191-199","journal-title":"Arch Dermatol Res"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jdermsci.2019.12.002","volume":"97","author":"Li Q.","year":"2020","unstructured":"Li Q.; Fang H.; Dang E.; Wang G.; The role of ceramides in skin homeostasis and inflammatory skin diseases. J Dermatol Sci  2020,97(1),2-8","journal-title":"J Dermatol Sci"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"120826","DOI":"10.1016\/j.ijpharm.2021.120826","volume":"605","author":"Yang X.","year":"2021","unstructured":"Yang X.; Tang Y.; Wang M.; Co-delivery of methotrexate and nicotinamide by cerosomes for topical psoriasis treatment with enhanced efficacy. Int J Pharm  2021,605,120826","journal-title":"Int J Pharm"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/ddg.12615","volume":"13","author":"Tha\u00e7i D.","year":"2015","unstructured":"Tha\u00e7i D.; Augustin M.; Krutmann J.; Luger T.; Importance of basic therapy in psoriasis. J Dtsch Dermatol Ges  2015,13(5),415-418","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"120264","DOI":"10.1016\/j.ijpharm.2021.120264","volume":"596","author":"Vovesn\u00e1 A.","year":"2021","unstructured":"Vovesn\u00e1 A.; Zhigunov A.; Balouch M.; Zbytovsk\u00e1 J.; Ceramide liposomes for skin barrier recovery: A novel formulation based on natural skin lipids. Int J Pharm  2021,596,120264","journal-title":"Int J Pharm"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ejps.2017.02.030","volume":"101","author":"Abdelgawad R.","year":"2017","unstructured":"Abdelgawad R.; Nasr M.; Moftah N.H.; Hamza M.Y.; Phospholipid membrane tubulation using ceramide doping \u201cCerosomes\u201d: Characterization and clinical application in psoriasis treatment. Eur J Pharm Sci  2017,101,258-268","journal-title":"Eur J Pharm Sci"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10717544.2020.1859000","volume":"28","author":"Albash R.","year":"2021","unstructured":"Albash R.; Yousry C.; Al-Mahallawi A.M.; Alaa-Eldin A.A.; Utilization of PEGylated cerosomes for effective topical delivery of fenticonazole nitrate: in-vitro characterization, statistical optimization, and in-vivo assessment. Drug Deliv  2021,28(1),1-9","journal-title":"Drug Deliv"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1016\/j.vaccine.2015.02.074","volume":"33","author":"Edens C.","year":"2015","unstructured":"Edens C.; Collins M.L.; Goodson J.L.; Rota P.A.; Prausnitz M.R.; A microneedle patch containing measles vaccine is immunogenic in non-human primates. Vaccine  2015,33(37),4712-4718","journal-title":"Vaccine"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.biopha.2017.07.019","volume":"93","author":"Ita K.","year":"2017","unstructured":"Ita K.; Dissolving microneedles for transdermal drug delivery: Advances and challenges. Biomed Pharmacother  2017,93,1116-1127","journal-title":"Biomed Pharmacother"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jconrel.2017.11.048","volume":"270","author":"Rzhevskiy A.S.","year":"2018","unstructured":"Rzhevskiy A.S.; Singh T.R.R.; Donnelly R.F.; Anissimov Y.G.; Microneedles as the technique of drug delivery enhancement in diverse organs and tissues. J Control Release  2018,270,184-202","journal-title":"J Control Release"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1517\/17425247.4.1.19","volume":"4","author":"Sivamani R.K.","year":"2007","unstructured":"Sivamani R.K.; Liepmann D.; Maibach H.I.; Microneedles and transdermal applications. Expert Opin Drug Deliv  2007,4(1),19-25","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jsps.2017.04.034","volume":"25","author":"Qin X.","year":"2017","unstructured":"Qin X.; Chen C.; Zhang Y.; Acitretin modulates HaCaT cells proliferation through STAT1- and STAT3-dependent signaling. Saudi Pharm J  2017,25(4),620-624","journal-title":"Saudi Pharm J"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0169-409X(00)00138-1","volume":"46","author":"Pikal M.J.","year":"2001","unstructured":"Pikal M.J.; The role of electroosmotic flow in transdermal iontophoresis. Adv Drug Deliv Rev  2001,46(1-3),281-305","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.03.053","volume":"317","author":"Subramony J.A.","year":"2006","unstructured":"Subramony J.A.; Sharma A.; Phipps J.B.; Microprocessor controlled transdermal drug delivery. Int J Pharm  2006,317(1),1-6","journal-title":"Int J Pharm"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"120601","DOI":"10.1016\/j.ijpharm.2021.120601","volume":"602","author":"Fukuta T.","year":"2021","unstructured":"Fukuta T.; Tanaka D.; Inoue S.; Michiue K.; Kogure K.; Overcoming thickened pathological skin in psoriasis via iontophoresis combined with tight junction-opening peptide AT1002 for intradermal delivery of NF-\u03baB decoy oligodeoxynucleotide. Int J Pharm  2021,602,120601","journal-title":"Int J Pharm"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/ddr.21492","volume":"80","author":"Singhvi G.","year":"2019","unstructured":"Singhvi G.; Manchanda P.; Hans N.; Dubey S.K.; Gupta G.; Microsponge: An emerging drug delivery strategy. Drug Dev Res  2019,80(2),200-208","journal-title":"Drug Dev Res"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"101347","DOI":"10.1016\/j.jddst.2019.101347","volume":"55","author":"Devi N.","year":"2020","unstructured":"Devi N.; Kumar S.; Prasad M.; Rao R.; Eudragit RS100 based microsponges for dermal delivery of clobetasol propionate in psoriasis management. J Drug Deliv Sci Technol  2020,55,101347","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"120571","DOI":"10.1016\/j.ijpharm.2021.120571","volume":"601","author":"Guimar\u00e3es D.","year":"2021","unstructured":"Guimar\u00e3es D.; Cavaco-Paulo A.; Nogueira E.; Design of liposomes as drug delivery system for therapeutic applications. Int J Pharm  2021,601,120571","journal-title":"Int J Pharm"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/978-981-33-4497-6_8","author":"Shah P.","year":"2021","unstructured":"Shah P.; Jariwala R.; Kapadiya S.; Sabale V.P.; Patel P.; Chaudhari P.M.; Niosomes: A novel nanometric vesicular system for drug delivery. Nanocarriers: Drug Delivery System  2021,201-226","journal-title":"Nanocarriers: Drug Delivery System"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"N8","DOI":"10.1111\/j.1750-3841.2011.02517.x","volume":"77","author":"Patel M.R.","year":"2012","unstructured":"Patel M.R.; San Martin-Gonzalez M.F.; Characterization of ergocalciferol loaded solid lipid nanoparticles. J Food Sci  2012,77(1),N8-N13","journal-title":"J Food Sci"},{"key":"ref=129","author":"Sunilendu B.R.","year":"2011","unstructured":"Sunilendu B.R.; Shafiq S.; Jitendra D.P.; Jinesh S.P.; Topical pharmaceutical compositions containing nanodroplets for the treatment psoriasis.  2011"},{"key":"ref=130","author":"Juntao L.X.W.","year":"2017","unstructured":"Juntao L.X.W.; Changying S.; Alexa B.; Walter H.; Lipidic compoundtelodendrimer hybrid nanoparticles and methods of making and uses thereof.  2017"},{"key":"ref=131","author":"Zheng YMS","year":"2018","unstructured":"Zheng YMS; A kind of Celastrol or tripterine derivate vesica and preparation method thereof China.  2018"},{"key":"ref=132","author":"Makatia MC","year":"2019","unstructured":"Makatia MC; Tomdin Y P; John B; Onurji AC; Antonios OA; Nanoparticle-based therapy for inflammatory diseases.  2019"},{"key":"ref=133","author":"Raghavan P.R.","year":"2014","unstructured":"Raghavan P.R.; Metadichol\u00ae liquid and gel nanoparticle formulations.  2014"},{"key":"ref=134","author":"Zhao lc","year":"2017","unstructured":"Zhao lc; Roy L; Van DP; Cyclodextrin-based polymers for therapeutic delivery.  2017"},{"key":"ref=135","unstructured":"Life care innovations, Psorisome Gel. Available from:  https:\/\/www.lifecareinnovations.com\/psorisome-gel.php (Accessed on: 20 aug, 2022)."},{"key":"ref=136","unstructured":"Life care innovations, Lipotar S Gel. Available from:  https:\/\/www.lifecareinnovations.com\/lipotar.php (Accessed on: 20th aug, 2022)."},{"key":"ref=137","unstructured":"Formulation and Clinical Evaluation of Ethosomal and Liposomal Preparations of Anthralin in Psoriasis. NCT03348462, Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03348462"},{"key":"ref=138","unstructured":"Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis. NCT00924950, Available from:  https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00924950"}],"container-title":["Recent Patents on Nanotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1872210517666230601124620","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/217554\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1872210517666230601124620","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T12:34:19Z","timestamp":1715258059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/217554\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":138,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1872210517666230601124620","relation":{},"ISSN":["1872-2105"],"issn-type":[{"value":"1872-2105","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-12-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}